12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

08/06/2016 - 7 minutes

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016.

asco_annual_meeting_2016_europeShortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical Oncology, it ran from 3rd to 7th of June and was an opportunity for many companies to present their latest achievements in cancer therapies.

ASCO 2015 already featured many European breakthroughs, and we also covered some of the work to be presented this year, such as Ganymed’s ideal antibodies.

Now that this year’s event has come to an end, we will take a closer look at the work of European Biotechs presented at this important conference…

Companies in no particular order

asco_2016_vaximm_bacterial_cancer_vaccine

As a Swiss-German Biotech, Vaximm is developing oral T-cell immunotherapies.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member